Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Global Melanoma Drugs Market 2019 Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2025on January 27, 2020 at 10:26 pm
A recent report provides crucial insights along with application based and forecast information in the Global Melanoma Drugs Market. The report provides a comprehensive analysis of key factors that ...
- Researchers develop new isolated limb infusion method for melanoma treatmenton January 27, 2020 at 10:04 am
The increasing trend among Estonians to travel to southern counties is also likely to play a role in this. Of all the types of skin cancer (including e.g. basal cell carcinoma and squamous cell ...
- Doctors and immunologists implement a new approach for melanoma treatmenton January 27, 2020 at 8:29 am
Of all the types of skin cancer (including e.g. basal cell carcinoma and squamous cell carcinoma), melanoma has the worst prognosis. Melanoma is considered to have the highest metastatic potential, ...
- B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2on January 27, 2020 at 2:12 am
In order to elucidate the mechanism, we performed functional analyses of B4GALNT1-overexpressing cells. We analyzed ganglioside pattern on four melanoma and two neuroblastoma cell lines by high ...
- Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1on January 23, 2020 at 2:11 am
Here, we identify sphingosine kinase-1 (SK1) as a key regulator of anti-tumor immunity. Increased expression of SK1 in tumor cells is significantly associated with shorter survival in metastatic ...
- This Simple Test Predicts Which Melanoma Patients Are At Risk Of Cancer Recurrenceon January 22, 2020 at 1:54 am
Per recent estimates, about 96,480 Americans will be diagnosed with melanoma this year Although primary melanomas can be cured, some can spread or recur Scientists discover a new test to evaluate ...
- NAU scientists study zebrafish to find powerful melanoma-fighting drugson January 21, 2020 at 8:42 am
Melanoma is the most lethal type of skin cancer and unusually common in Arizona, where residents are exposed to higher-than-average amounts of ultraviolet radiation. However, Northern Arizona ...
- Melanoma Scanner Market 2020 Analysis Research and Development Forecast by 2025on January 21, 2020 at 3:52 am
New York, January 21, 2020: The global Melanoma Scanner market is segregated on the basis of Product Type as Standalone Melanoma Scanner and Handheld Melanoma Scanner. Based on Skin Melanoma the ...
- New test predicts which melanoma patients are at risk of cancer recurrence, spreadon January 20, 2020 at 3:05 pm
Researchers from a Boston hospital worked with colleagues around the world are presenting a new technique to test skin cancer cells.
- New technique predicts which melanoma patients are at risk for cancer recurrence, spreadon January 20, 2020 at 8:06 am
For most patients, melanoma begins with a small, pigmented spot on their skin that they notice starts to change. Many primary melanomas can be cured by having this lesion removed, but melanoma can ...
via Bing News